Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Insulin Formulations: Types and Delivery

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...

Insulin: Dosing Regimen and Adverse Effects

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

Insulin: Biosynthesis, Chemistry, and Preparation

Insulin: Biosynthesis, Chemistry, and Preparation

The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same authorSame journal

Incident Diabetic Retinopathy after Adjunctive Tirzepatide Treatment for 1 Year in Adults with Type 1 Diabetes.

Diabetes technology & therapeutics·2026

Same author

Neuro-symbolic artificial intelligence in medicine.

Nature biomedical engineering·2026

Same author

Participants' experiences of living with cystic fibrosis related diabetes and using a hybrid closed-loop system to support self-management: qualitative study.

BMC endocrine disorders·2026

Same author

Cambridge hybrid closed-loop use in very young children with type 1 diabetes: Parental expectancies during long-term home use.

Diabetic medicine : a journal of the British Diabetic Association·2026

Same author

Real-World Evidence Assessment of the Risk of Nonfatal Stroke in Patients Prescribed SGLT2 Inhibitors.

Stroke research and treatment·2026

Same author

Automated Insulin Delivery: Great Strides in the Past, Great Needs for the Future.

Diabetes care·2026

Search research articles

Related Experiment Video

Updated: Sep 17, 2025

Improving IV Insulin Administration in a Community Hospital

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Registration and Real-Life Studies on Automated Insulin Delivery Systems.

Halis Kaan Akturk¹, Sue A Brown², Roy W Beck³

¹Barbara Davis Center for Diabetes, University of Colorado Denver Anschutz Medical Campus, Aurora, Colorado, USA.

Diabetes Technology & Therapeutics

|July 1, 2025

Summary

Automated insulin delivery (AID) systems improve glycemic control and quality of life for type 1 diabetes (T1D) patients. Real-world studies confirm the safety and effectiveness of FDA-approved AID systems across all age groups.

Keywords:

CGM CSII HbA1c artificial pancreas hyperglycemia hypoglycemia insulin pump time below range time in range

More Related Videos

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

An In Ovo Model for Testing Insulin-mimetic Compounds

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

Related Experiment Videos

Last Updated: Sep 17, 2025

Improving IV Insulin Administration in a Community Hospital

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

An In Ovo Model for Testing Insulin-mimetic Compounds

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

Area of Science:

Endocrinology
Metabolic Diseases
Biomedical Engineering

Background:

Intensive insulin therapy (IIT) demonstrated benefits for type 1 diabetes (T1D) complications but increased hypoglycemia risk.
Automated insulin delivery (AID) systems are now standard care for T1D management.

Purpose of the Study:

To review registration and real-life studies of FDA-approved AID systems for T1D.
To assess the safety and efficacy of AID systems in diverse patient populations.

Main Methods:

Systematic literature search of MEDLINE (PubMed) database.
Inclusion of studies with longest duration and largest participant numbers.
Review of both registration and real-world data for AID systems.

Main Results:

AID systems have improved glycemic metrics (HbA1c, time in range, time below range) and quality of life in T1D patients.
Studies indicate safe and effective use of AID systems across all age groups.
Real-life data corroborate findings from AID system registration studies.

Conclusions:

FDA-approved AID systems demonstrate consistent glycemic improvements and safety in T1D management.
Real-world evidence validates the efficacy of AID systems reported in clinical trials.
AID systems represent a significant advancement in T1D care.